New drug combo plus radiation targets tough uterine cancer
NCT ID NCT05603910
First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 5 times
Summary
This early-stage trial is testing whether combining two cancer drugs (lenvatinib and pembrolizumab) with a shorter course of pelvic radiation is safe for people with recurrent or unresectable endometrial cancer. The study aims to find the best dose of lenvatinib when used in this triple therapy. About 18 participants will be enrolled to monitor side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenvatinib (Lenvima) and pembrolizumab (Keytruda)
- What this could lead to
- If this combination is safe, it could lead to a new treatment option for people with recurrent or unresectable endometrial cancer that hasn't responded to standard therapy.
- What could go wrong
- This is a very early phase 1 trial with only 18 participants, so the main goal is safety, not effectiveness. The combination of drugs and radiation may cause significant side effects, and it's unknown if it will actually shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- Hormone blocker plus targeted drug shows promise against tough uterine cancer
- Cancer drug combo tested for rare gene mutation – but trial stopped early
- New drug duo shows promise for Tough-to-Treat endometrial cancer
- Custom-Made cancer vaccine shows promise in advanced tumors
- Experimental drug plus radiation shows promise for recurrent gynecologic cancers